Latest News and Press Releases

CUPERTINO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function,...

Data reinforce brilaroxazine’s differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion...

CUPERTINO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated...

CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel...

CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical...